AGENDA

INTRODUCTION AND COVID-19 UPDATE
Dave Ricks, Chairman and Chief Executive Officer

R&D UPDATE
Dan Skovronsky, M.D., Ph.D., Chief Scientific Officer

Q1 2020 FINANCIAL RESULTS
Josh Smiley, Chief Financial Officer

CLOSING REMARKS
Dave Ricks, Chairman and Chief Executive Officer

QUESTION AND ANSWER SESSION
This presentation contains forward-looking statements that are based on management's current expectations, but actual results may differ materially due to various factors. The company's results may be affected by factors including, but not limited to, the risks and uncertainties in pharmaceutical research and development; competitive developments; regulatory actions; the extent and duration of the effects of the COVID-19 pandemic; litigation and investigations; business development transactions; economic conditions; and changes in laws and regulations, including health care reform.

For additional information about the factors that affect the company's business, please see the company's latest Forms 10-K, 10-Q, and any 8-Ks filed with the Securities and Exchange Commission.

The company undertakes no duty to update forward-looking statements except as required by applicable law.
COVID-19 LILLY RESPONSE

MAINTAIN SUPPLY OF AND ACCESS TO MEDICINE

- All manufacturing facilities limited to essential personnel
- Additional precautions at all manufacturing sites
- Insulin Value Program caps monthly patient out-of-pocket at $35/Rx

REDUCE STRAIN ON MEDICAL SYSTEM

- Paused new clinical trial starts and enrollment for most programs
- Suspended in-person customer visits
- PPE donation and medical volunteers
- Antibody therapies through collaboration with AbCellera
- Baricitinib being assessed as anti-inflammatory approach
- Ang2 antibody in Phase 2 trial

DEVELOP TREATMENTS FOR COVID-19

- Travel restrictions and remote work since early March
- Physical and mental health resources available

KEEP EMPLOYEES SAFE

- #INThisTogether community awareness campaign
- Funding relief efforts and doubling employee match for COVID-19 giving
- Created drive-through COVID-19 testing facility
- Paid volunteer opportunities for employees

SUPPORT OUR COMMUNITIES
POTENTIAL COVID-19 TREATMENTS

Baricitinib
JAK1 / JAK2 inhibitor
- Part of NIAID’s Adaptive COMD-19 Treatment Trial
- Anti-inflammatory activity hypothesized to be beneficial in treating COMD-19¹
- Numerous investigator-led trials ongoing
- Initial results from NIAID trial expected in June

LY3127804
Angiopoietin 2 (Ang2) mAb
- Ang2 known to be elevated in patients with ARDS
- Phase 2 trial recently initiated
- Enrolling patients with pneumonia who are hospitalized due to COMD-19
- Results expected in June

Antibody Therapies
- Collaboration with AbCellera
- Assessing multiple fully human antibodies identified from early COVID-19 survivors
- Plan to submit IND by end of May

¹The approved rheumatoid arthritis indication includes warnings about risk for developing serious infection
# Lilly Select NME and Nilex Pipeline

**April 20, 2020**

<table>
<thead>
<tr>
<th>Legend</th>
<th>Movement Since January 27, 2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>NME</td>
<td>Achieved Milestone</td>
</tr>
<tr>
<td>NILEX</td>
<td></td>
</tr>
<tr>
<td>Commercial Collaboration</td>
<td>Removal</td>
</tr>
</tbody>
</table>

### Phase 1
- **CD73 Inhibitor** 
  - Cancer
- **N3PG Aβ MAB** 
  - Alzheimer’s
- **GIP6GLP Coagonist Peptide** 
  - Diabetes
- **ANGPTL3/8 MAB** 
  - CVD
- **GLP-1R NPA** 
  - Diabetes
- **OGlcNAcase Inh**
  - Alzheimer’s
- **BTK Inhibitor** 
  - Cancer
- **PD-1 MAB Agonist** 
  - Immunology
- **Pacap38 Mab** 
  - Pain
- **BTLA MAB Agonist** 
  - Immunology
- **Aur A Kinase Inhibitor** 
  - Cancer
- **IL-33 MAB Immunology**

### Phase 2
- **CD3 Immunology**
  - Cancer
- **Kras G12C Inhibitor** 
  - Cancer
- **TAU Morphomer** 
  - Alzheimer’s
- **SSTR4 Agonist**
  - Pain
- **TRPA1 Agonist**
  - Pain
- **D1 Pam I**
  - Dementia
- **ERK Inhibitor**
  - Cancer
- **IL-2 Conjugate Immunology**
- **Gof 15 Agonist Diabetes**
- **Oxyntomodulin Diabetes**
- **Cxcr1/2l MAB Immunology**

### Phase 3
- **Tirzepatide** 
  - NASH
  - Pancreatic Cancer
- **Olaratumab** 
  - Prostate Cancer
- **Abemaciclib**
  - Adjuvant Breast Cancer
- **Mirikizumab**
  - Crohn’s Disease
  - Ulcerative Colitis
- **Empagliflozin**
  - Heart Failure
  - Chronic Kidney Disease
- **Selpercatinib**
  - 1L Med Thyroid Cancer
  - 1L NSCLC
- **Tirzepatide**
  - Diabetes
  - LEBRiKizumab
  - Atopic Dermatitis
- **Solanezumab**
  - Preclinical AD
  - Mirikizumab
  - Pioriasis

**Legend**
- **Baricitinib**
  - Covid-19
  - Atopic Eczema
  - Systemic Lupus Erythematosus
- **Abemaciclib**
  - Adjuvant Breast Cancer
  - Cancer Pain
- **Mirikizumab**
  - Crohn’s Disease
  - Ulcerative Colitis
- **Empagliflozin**
  - Heart Failure
  - Chronic Kidney Disease
- **Selpercatinib**
  - 1L Med Thyroid Cancer
  - 1L NSCLC
- **Baricitinib**
  - Obesity
  - Systemic Lupus Erythematosus
  - Atopic Dermatitis
  - Non-Radiographic AxSpA
  - Osteoarthritis Pain
  - Osteoarthritis Pain
  - Pediatric Psoriasis

**2020 Q1 Earnings**

Not for promotional use
POTENTIAL KEY EVENTS 2020

Phase 3 Initiations
- Tirzepatide CV Outcome Study (H2H vs. dulaglutide)
- Selpercatinib for 1L NSCLC³
- Selpercatinib for 1L medullary thyroid cancer³

Phase 3 Top-Line Data Disclosures
- Empagliflozin CHF outcomes study HFrEF¹
- Tirzepatide for type 2 diabetes (first of five)
- Baricitinib for atopic dermatitis (last two of five studies)
- Mirikizumab in psoriasis (first of two studies)
- Mirikizumab in ulcerative colitis (induction data)
- Solanezumab for dominantly inherited Alzheimer’s

Medical Meeting Presentations
- Dulaglutide alternate doses for type 2 diabetes
- LOXO-305 additional data from Phase 1/2 study

Regulatory Submissions
- Baricitinib for atopic dermatitis (US/EU/J)
- Tanezumab osteoarthritis pain (US²/EU/J)
- Selpercatinib for NSCLC and thyroid cancers (EU/J³)

Regulatory Actions
- Dulaglutide alternate doses for type 2 diabetes (US/EU)
- Dulaglutide REWIND CV outcomes study (US)
- Empagliflozin + linagliptin + metformin XR for type 2 diabetes (US¹)
- Ultra rapid lispro for type 1 and type 2 diabetes (US/EU/J)
- Flortaucipir as a PET imaging agent (US)

- Mirikizumab for episodic cluster headache (EU)
- Ixekizumab for non-radiographic axial spondyloarthritis (US/EU/J)
- Ixekizumab for radiographic axial spondyloarthritis (EU)
- Ramucirumab for 1L EGFR NSCLC cancer (US/EU/J)
- Selpercatinib for NSCLC and thyroid cancers (US)

³ occurred in Q4 2019
¹ in collaboration with Boehringer Ingelheim
² in collaboration with Pfizer
³ in collaboration with Pfizer

Not for promotional use
## COVID-19 DYNAMICS IMPACTING OUTLOOK

### REASONS FOR OPTIMISM

- Strong underlying fundamentals of business
- Transitory nature of delayed physician visits
- Unchanged unmet need for new and existing medicines
- Speed and agility of pharma industry working together to solve the problem
- Collaboration across public and private spheres

### MID-TERM RISKS

- Reduction in New Therapy Starts most acute for newest brands
- Rise in unemployment and payer mix changes
- Inevitable fiscal pressure on government funded health care
- Delays in clinical trial activity
**Grow Revenue**
- 15% revenue growth in Q1; 16% in constant currency
- Revenue growth driven by:
  - 22% volume growth
  - Key growth products accounted for over half of total revenue
  - Estimated COVID-19 impact ~$250 million

**Improve Productivity**
- Non-GAAP:
  - Gross margin was 80.3% (80.6% excluding FX impact on international inventories sold)
  - Operating margin was 30.1%

**Create Long-Term Value**
- Completed the acquisition of Dermira, Inc.
- Completed $0.5 billion in share repurchases
- Distributed nearly $0.7 billion via dividends

**Speed Life-Changing Medicines**
- Approval of ultra-rapid lispro Lyumjev in Europe and Japan
- Approval of Trulicity® REWIND study for a CV outcomes label claim in the U.S.
- Approval of Taltz® for pediatric patients with moderate-to-severe plaque psoriasis
KEY EVENTS SINCE THE LAST EARNINGS CALL

COMMERCIAL

- Announced the Lilly Insulin Value Program, allowing anyone with commercial insurance and those without insurance to fill their monthly prescription of Lilly insulin for $35. The program covers most Lilly insulins including all Humalog® formulations; and
- Announced participation in the Centers for Medicare & Medicaid Services (CMS) Part D Senior Savings Model that aims to improve the affordability of insulin for seniors in Medicare Part D. Beginning January 1, 2021, seniors in participating Medicare Part D insurance plans will see out-of-pocket costs for covered Lilly insulins reduced to no more than $35 per 30-day supply.

REGULATORY

- The U.S. Food and Drug Administration (FDA) approved Trulicity for the reduction of major adverse cardiovascular events in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors;
- The FDA approved Taltz for the treatment of pediatric patients with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy;
- The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion for Lilly’s new mealtime insulin, Lyumjev, for use in adults with type 1 and type 2 diabetes to reduce blood glucose;
- The FDA granted Fast Track designation to empagliflozin, part of our collaboration with Boehringer Ingelheim, to reduce the risk of kidney disease progression and cardiovascular death in adults with chronic kidney disease;
- The FDA granted Breakthrough Therapy designation to baricitinib, part of our collaboration with Incyte, for treatment of alopecia areata; and
- The FDA issued a complete response for empagliflozin 2.5 mg as an adjunct to insulin for adults with type 1 diabetes. The letter indicates that the FDA is unable to approve the application in its current form.

CLINICAL

- In the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) Study showed that solanezumab did not meet the primary endpoint. At this time, Lilly does not plan to pursue a submission for solanezumab in people with dominantly inherited Alzheimer’s disease;
- Mirikizumab met the co-primary and key secondary endpoints in OASIS-1, a 52-week Phase 3 trial in moderate-to-severe plaque psoriasis. OASIS-2, the second Phase 3 trial will be completed later in 2020; and
- Completed the Phase 4 Taltz IXORA-R study in patients with moderate-to-severe psoriasis. As previously disclosed, Taltz achieved superiority compared to guselkumab on all primary and key secondary endpoints at week 12. Additionally, Taltz demonstrated non-inferiority to guselkumab on the final secondary endpoint at week 24.

BUSINESS DEVELOPMENT & OTHER

- Entered into an agreement with AbCellera to co-develop antibody products for the potential treatment and prevention of COVID-19. The collaboration will leverage AbCellera’s rapid pandemic response platform, developed under the DARPA Pandemic Prevention Platform (P3) Program, and Lilly’s global capabilities for rapid development, manufacturing and distribution of therapeutic antibodies;
- Announced an exclusive global licensing and research collaboration with Sitryx, a biopharmaceutical company focused on regulating cell metabolism to develop disease modifying therapeutics in immuno-oncology and immuno-inflammation. The collaboration will study up to four novel preclinical targets identified by Sitryx; and
- Completed the acquisition of Dermira, Inc.
## RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION; CERTAIN LINE ITEMS (UNAUDITED)

**Note:** Numbers may not add due to rounding; see slide 26 for a complete list of significant adjustments.

<table>
<thead>
<tr>
<th></th>
<th>GAAP Reported</th>
<th>Adjustments</th>
<th>Non-GAAP Adjusted</th>
<th>Non-GAAP Adjusted Change</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>TOTAL REVENUE</strong></td>
<td>$5,860</td>
<td>-</td>
<td>$5,860</td>
<td>15%</td>
</tr>
<tr>
<td><strong>GROSS MARGIN</strong></td>
<td>79.3%</td>
<td>1.0%</td>
<td>80.3%</td>
<td>0.1pp</td>
</tr>
<tr>
<td><strong>TOTAL OPERATING EXPENSE</strong></td>
<td>3,054</td>
<td>(112)</td>
<td>2,942</td>
<td>7%</td>
</tr>
<tr>
<td><strong>OPERATING INCOME</strong></td>
<td>1,591</td>
<td>171</td>
<td>1,762</td>
<td>32%</td>
</tr>
<tr>
<td><strong>OPERATING MARGIN</strong></td>
<td>27.1%</td>
<td>3.0%</td>
<td>30.1%</td>
<td>3.9pp</td>
</tr>
<tr>
<td><strong>OTHER INCOME (EXPENSE)</strong></td>
<td>89</td>
<td>-</td>
<td>89</td>
<td>4%</td>
</tr>
<tr>
<td><strong>EFFECTIVE TAX RATE</strong></td>
<td>13.3%</td>
<td>0.3%</td>
<td>13.6%</td>
<td>0.7pp</td>
</tr>
<tr>
<td><strong>NET INCOME</strong></td>
<td>$1,457</td>
<td>142</td>
<td>$1,599</td>
<td>29%</td>
</tr>
<tr>
<td><strong>EPS</strong></td>
<td>$1.60</td>
<td>0.15</td>
<td>$1.75</td>
<td>32%</td>
</tr>
</tbody>
</table>

*Millions; except per share data*
## PRICE/RATE/VOLUME EFFECT ON REVENUE

### Q1 2020

<table>
<thead>
<tr>
<th>Region</th>
<th>Amount (Millions)</th>
<th>Price (%)</th>
<th>FX Rate (%)</th>
<th>Volume (%)</th>
<th>Total (%)</th>
<th>CER (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>U.S.</td>
<td>$3,329</td>
<td>(4)%</td>
<td>—%</td>
<td>19%</td>
<td>15%</td>
<td>15%</td>
</tr>
<tr>
<td>EUROPE</td>
<td>1,061</td>
<td>(3)%</td>
<td>(3)%</td>
<td>24%</td>
<td>18%</td>
<td>21%</td>
</tr>
<tr>
<td>JAPAN</td>
<td>592</td>
<td>(3)%</td>
<td>1%</td>
<td>11%</td>
<td>9%</td>
<td>8%</td>
</tr>
<tr>
<td>CHINA</td>
<td>267</td>
<td>(64)%</td>
<td>(3)%</td>
<td>93%</td>
<td>27%</td>
<td>30%</td>
</tr>
<tr>
<td>REST OF WORLD</td>
<td>610</td>
<td>(2)%</td>
<td>(2)%</td>
<td>15%</td>
<td>12%</td>
<td>14%</td>
</tr>
<tr>
<td>TOTAL REVENUE</td>
<td>$5,860</td>
<td>(6)%</td>
<td>(1)%</td>
<td>22%</td>
<td>15%</td>
<td>16%</td>
</tr>
</tbody>
</table>

Note: Numbers may not add due to rounding.

CER = price change + volume change

Not for promotional use
KEY PRODUCTS DRIVING WW VOLUME GROWTH

Contribution to 22% Q1 WW Volume Growth

<table>
<thead>
<tr>
<th>Key Products*</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alimta</td>
<td>2.4%</td>
</tr>
<tr>
<td>Humalog</td>
<td>2.2%</td>
</tr>
<tr>
<td>All Other</td>
<td>0.2%</td>
</tr>
<tr>
<td>Forteo</td>
<td>-0.4%</td>
</tr>
<tr>
<td>Lartruvo</td>
<td>-0.9%</td>
</tr>
<tr>
<td>LOE Products**</td>
<td>-1.8%</td>
</tr>
</tbody>
</table>

**Numbers do not add due to rounding**

Basaglar®, Jardiance®, and Tradjenta® are part of the Boehringer
Ingelheim and Lilly Diabetes Alliance

* Includes Baqsimi™, Basaglar, Cyramza®, Emgality®, Jardiance, Olumiant®, Taltz, Trulicity, Txyx®, and Verzenio®

** LOE: loss of exclusivity; includes Axiron®, Cialis®, Cymbalta®, Effient®, Evista®, Strattera®, and Zyprexa®

2020 Q1 EARNINGS
UPDATE ON KEY GROWTH PRODUCTS

BAQSIMI
- Approved July 2019 in U.S., NBRx SOM over 26% at end of Q1 2020

TYVYT
- Added to China's National Drug Reimbursement List in 2020

EMGALITY
- U.S. TRx SOM increased by 22pp vs. Q1 2019
- U.S. NBRx SOM 45% at the end of Q1 2020

VERZENIO
- Announced positive OS data in HR+, HER2- mBC in Q3 2019
- U.S. TRx grew over 43% vs. Q1 2019

OLUMIANT
- OUS Sales grew 70% vs. Q1 2019

TALTZ
- IL-17 class leader in U.S. NBRx and NTS SOM in dermatology
- Total molecule U.S. TRx grew nearly 37% vs. Q1 2019

BASAGLAR
- U.S. TRx 21% SOM at end of Q1 2020

JARDIANCE
- Market leader in U.S. TRx SOM 56% and NTS SOM over 62%
- Class growth strong in U.S. TRx +25% and NTS +35% vs. Q1 2019

CYRAMZA
- Robust WW sales growth +21% vs. Q1 2019

TRULICITY
- U.S. TRx leader with over 45% SOM
- U.S. GLP-1 class grew 33% vs. Q1 2019

Note: Jardiance is sold by Boehringer Ingelheim; Lilly records as revenue its share of Jardiance gross margin. Jardiance and Basaglar are part of the Boehringer Ingelheim and Lilly Diabetes Alliance.
Q1 2020 Capital Allocation

- R&D*: $1.2 billion
- Capital Investments: $0.3 billion
- Business Development: $0.9 billion
- Dividend: $0.7 billion
- Share Repurchase: $0.5 billion

*After-tax (non-GAAP)
## 2020 GUIDANCE

<table>
<thead>
<tr>
<th></th>
<th>Prior</th>
<th>Updated</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>TOTAL REVENUE</td>
<td>$23.7 - $24.2 billion</td>
<td>unchanged</td>
<td>Reflects potential variability in timing and depth of healthcare utilization in Q2-Q4</td>
</tr>
<tr>
<td>GROSS MARGIN % (GAAP)</td>
<td>approx. 79%</td>
<td>unchanged</td>
<td></td>
</tr>
<tr>
<td>GROSS MARGIN % (NON-GAAP)</td>
<td>approx. 81%</td>
<td>unchanged</td>
<td></td>
</tr>
<tr>
<td>MKTG, SELLING &amp; ADMIN.</td>
<td>$6.2 - $6.4 billion</td>
<td>unchanged</td>
<td>Reflects expected savings from reduced promotion and travel and investment in digital outreach</td>
</tr>
<tr>
<td>RESEARCH &amp; DEVELOPMENT</td>
<td>$5.6 - $5.9 billion</td>
<td>unchanged</td>
<td>Reflects expected savings from pause in clinical trial activities and investment in potential COVID-19 treatments</td>
</tr>
<tr>
<td>OTHER INCOME/(EXPENSE)</td>
<td>$(250) – $(100) million</td>
<td>$(150) – $0 million</td>
<td>Updated to reflect Q1 equity portfolio gains</td>
</tr>
<tr>
<td>TAX RATE</td>
<td>approx. 15%</td>
<td>unchanged</td>
<td></td>
</tr>
<tr>
<td>EARNINGS PER SHARE (GAAP)</td>
<td>$6.18 – $6.28</td>
<td>$6.20 – $6.40</td>
<td>Widened to reflect the uncertainty of the COVID-19 impact</td>
</tr>
<tr>
<td>EARNINGS PER SHARE (NON-GAAP)</td>
<td>$6.70 – $6.80</td>
<td>$6.70 – $6.90</td>
<td>Widened to reflect the uncertainty of the COVID-19 impact</td>
</tr>
<tr>
<td>OPERATING INCOME % (GAAP)</td>
<td>28%</td>
<td>unchanged</td>
<td></td>
</tr>
<tr>
<td>OPERATING INCOME % (NON-GAAP)</td>
<td>31%</td>
<td>unchanged</td>
<td></td>
</tr>
</tbody>
</table>

Assumes GAAP and non-GAAP shares outstanding 912 million

Updated FX assumptions of 1.11 (Euro), 108 (Yen) and 7.07 (Renminbi)
CLOSING REMARKS

Lilly Drive-Through COVID-19 Testing Facility
Lilly unites caring with discovery to create medicines that make life better for people around the world.

Lilly
SUPPLEMENTARY SLIDES
Q1 2020 PERFORMANCE SUMMARY

- Q1 2020 volume-driven revenue growth of 15% (16% in constant currency)

- Operating income as a % of revenue improved nearly 400 bps vs. Q1 2019

- Progress on our innovation-based strategy, including three approvals

- Deployed nearly $0.7 billion to shareholders via the dividend and completed $0.5 billion of share repurchases
# 2020 Income Statement - Reported

<table>
<thead>
<tr>
<th></th>
<th>Q1 2020</th>
<th>Change</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Revenue</strong></td>
<td>$5,860</td>
<td>15%</td>
</tr>
<tr>
<td><strong>Gross Margin</strong></td>
<td>79.3%</td>
<td>1.7pp</td>
</tr>
<tr>
<td>*<em>Total Operating Expense</em></td>
<td>3,054</td>
<td>(8)%</td>
</tr>
<tr>
<td><strong>Operating Income</strong></td>
<td>1,591</td>
<td>NM</td>
</tr>
<tr>
<td><strong>Operating Margin</strong></td>
<td>27.1%</td>
<td>NM</td>
</tr>
<tr>
<td><strong>Other Income (Expense)</strong></td>
<td>89</td>
<td>4%</td>
</tr>
<tr>
<td><strong>Effective Tax Rate</strong></td>
<td>13.3%</td>
<td>NM</td>
</tr>
<tr>
<td><strong>Net Income</strong></td>
<td>$1,457</td>
<td>NM</td>
</tr>
<tr>
<td><strong>Earnings Per Share</strong></td>
<td>$1.60</td>
<td>NM</td>
</tr>
</tbody>
</table>

*Includes research and development expense, marketing, selling and administrative expense, acquired in-process research and development charges, and asset impairment, restructuring and other special charges.

NM - not meaningful

Millions; except per share data

[2020 Q1 Earnings](#)
NON-GAAP GROSS MARGIN % OF REVENUE

Individual quarter GM % of Revenue:
- with FX effect on int’l inv sold:
  - 2018: 78.6%, 79.8%, 80.2%, 80.6%, 80.2%, 81.0%, 79.6%, 79.9%, 80.3%
- w/o FX effect on int’l inv sold:
  - 2018: 81.5%, 80.9%, 80.3%, 80.1%, 80.2%, 80.2%, 78.9%, 79.6%, 80.6%

Note: The lines in the graph are moving annual totals (i.e. trailing 4 quarters) while the two rows of numbers are from specific quarters.
* 2018 has been reclassified to reflect divestiture of Elanco Animal Health in 2019.
NON-GAAP OPERATING MARGIN % OF REVENUE

Individual quarter GM % of Revenue:

- With FX effect on int’l inv sold:
  - 2018: 29.3%, 30.4%, 28.7%, 25.9%, 26.2%, 27.9%, 28.6%, 26.3%, 30.1%
  - 2019: 29.0%, 28.7%, 25.9%, 26.2%, 27.9%, 28.6%, 26.3%, 25.9%, 30.4%

- w/o FX effect on int’l inv sold:
  - 2018: 32.2%, 31.5%, 28.7%, 25.4%, 26.2%, 27.2%, 27.9%, 25.9%,
  - 2019: 32.0%, 28.7%, 25.4%, 26.2%, 27.2%, 27.9%, 25.9%,
  - 2020: 30.4%

Note: The lines in the graph are moving annual totals (i.e. trailing 4 quarters) while the two rows of numbers are from specific quarters.
* 2018 has been reclassified to reflect divestiture of Elanco Animal Health in 2019.

2020 Q1 EARNINGS
### EFFECT OF FX ON 2020 RESULTS

#### Year-on-Year Growth

<table>
<thead>
<tr>
<th></th>
<th>Q1 2020</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>With FX</td>
<td>w/o FX</td>
<td></td>
</tr>
<tr>
<td><strong>REPORTED</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TOTAL REVENUE</td>
<td>15%</td>
<td>16%</td>
<td></td>
</tr>
<tr>
<td>COST OF SALES</td>
<td>7%</td>
<td>6%</td>
<td></td>
</tr>
<tr>
<td>GROSS MARGIN</td>
<td>17%</td>
<td>19%</td>
<td></td>
</tr>
<tr>
<td>OPERATING EXPENSE</td>
<td>(8)%</td>
<td>(7)%</td>
<td></td>
</tr>
<tr>
<td>OPERATING INCOME</td>
<td>NM</td>
<td>NM</td>
<td></td>
</tr>
<tr>
<td>EARNINGS PER SHARE</td>
<td>NM</td>
<td>NM</td>
<td></td>
</tr>
<tr>
<td><strong>NON-GAAP</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TOTAL REVENUE</td>
<td>15%</td>
<td>16%</td>
<td></td>
</tr>
<tr>
<td>COST OF SALES</td>
<td>14%</td>
<td>14%</td>
<td></td>
</tr>
<tr>
<td>GROSS MARGIN</td>
<td>15%</td>
<td>16%</td>
<td></td>
</tr>
<tr>
<td>OPERATING EXPENSE</td>
<td>7%</td>
<td>8%</td>
<td></td>
</tr>
<tr>
<td>OPERATING INCOME</td>
<td>32%</td>
<td>34%</td>
<td></td>
</tr>
<tr>
<td>EARNINGS PER SHARE</td>
<td>32%</td>
<td>34%</td>
<td></td>
</tr>
</tbody>
</table>
# EPS RECONCILIATION

<table>
<thead>
<tr>
<th></th>
<th>Q1 2020</th>
<th>Q1 2019</th>
<th>Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS (REPORTED)</td>
<td>$1.60</td>
<td>$4.31</td>
<td>NM</td>
</tr>
<tr>
<td>ASSET IMPAIRMENT, RESTRUCTURING, AND OTHER SPECIAL CHARGES</td>
<td>0.06</td>
<td>0.44</td>
<td></td>
</tr>
<tr>
<td>AMORTIZATION OF INTANGIBLE ASSETS</td>
<td>0.05</td>
<td>0.04</td>
<td></td>
</tr>
<tr>
<td>ACQUIRED IN-PROCESS RESEARCH AND DEVELOPMENT</td>
<td>0.05</td>
<td>0.12</td>
<td></td>
</tr>
<tr>
<td>LARTRUVO CHARGES</td>
<td></td>
<td>0.13</td>
<td></td>
</tr>
<tr>
<td>REDUCED SHARES OUTSTANDING</td>
<td></td>
<td>0.03</td>
<td></td>
</tr>
<tr>
<td>DISCONTINUED OPERATIONS</td>
<td></td>
<td>(3.74)</td>
<td></td>
</tr>
<tr>
<td>EPS (NON-GAAP)</td>
<td>$1.75</td>
<td>$1.33</td>
<td>32%</td>
</tr>
</tbody>
</table>

Note: Numbers may not add due to rounding; see slide 26 for more details on these significant adjustments.
Q1 2020 NON-GAAP INFORMATION HAS BEEN ADJUSTED TO ELIMINATE:

- amortization of intangible assets primarily associated with costs of marketed products acquired or licensed from third parties totaling $54.4 million (pretax), or $0.05 per share (after-tax);
- acquired in-process R&D charges totaling $52.3 million (pretax), or $0.05 per share (after-tax), related to business development activity other than a business combination, related to Sitryx; and
- asset impairment, restructuring and other special charges, primarily acquisition and integration costs as part of the closing of the acquisition of Dermira, totaling $64.1 million (pretax), or $0.06 per share (after-tax).

Q1 2019 NON-GAAP INFORMATION HAS BEEN ADJUSTED TO ELIMINATE:

- discontinued operations of Elanco Animal Health business, substantially all the gain on the disposition, totaling a reduction of $3.74 per share (after-tax);
- assumption that the disposition of Elanco occurred at the beginning of the year and therefore include the benefit from the reduction in shares of common stock outstanding, totaling $0.03 per share (after-tax);
- amortization of intangible assets primarily associated with costs of marketed products acquired or licensed from third parties totaling $43.6 million (pretax), or $0.04 per share (after-tax);
- acquired in-process R&D charges totaling $136.9 million (pretax), or $0.12 per share (after-tax), related to business development activity other than a business combination, related to AC Immune SA and ImmuNext, Inc.;
- Charges related to the suspension of promotion of Lartruvo, totaling $96.7 million (pretax), or $0.13 per share (after-tax); and
- Charges primarily associated with the accelerated vesting of Loxo employee equity awards as a result of the closing of the acquisition of Loxo Oncology, totaling $411.8 million (pretax), or $0.44 per share (after-tax).
# COMPARATIVE EPS SUMMARY 2019/2020

<table>
<thead>
<tr>
<th></th>
<th>1Q19</th>
<th>2Q19</th>
<th>3Q19</th>
<th>4Q19</th>
<th>2019</th>
<th>1Q20</th>
<th>2Q20</th>
<th>3Q20</th>
<th>4Q20</th>
<th>2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reported</td>
<td>4.31</td>
<td>1.44</td>
<td>1.37</td>
<td>1.64</td>
<td>8.89</td>
<td>1.60</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-GAAP</td>
<td>1.33</td>
<td>1.50</td>
<td>1.48</td>
<td>1.73</td>
<td>6.04</td>
<td>1.75</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Note: Numbers may not add due to rounding.

For a complete reconciliation to reported earnings, see slide 26 and our earnings press release dated April 23, 2020.
Q1 2020 TRULICITY SALES INCREASED 40%

U.S. sales increased 40%
International sales increased 40%

Note: Numbers may not add due to rounding.

Source: IQVIA NPA TRx 3MMA, weekly data March 27, 2020
Q1 2020 TALTZ SALES INCREASED 76%

U.S. sales increased 81%
International sales increased 62%

Note: Numbers may not add due to rounding.

Source: IQVIA NPA TRx 3MMA, weekly data March 27, 2020
Note: TRx data is representative of the dermatology market
Q1 2020 BASAGLAR SALES INCREASED 21%

U.S. sales increased 16%
International sales increased 38%

Note: Numbers may not add due to rounding.

Source: IQVA NPA TRx 3MMA, weekly data March 27, 2020

Note: Basaglar is part of the Boehringer Ingelheim and Lilly Diabetes Alliance
Q1 2020 JARDIANCE SALES INCREASED 31%

U.S. sales increased 15%
International sales increased 57%

Not for promotional use

Millions

Source: IQVIA NPA TRx 3MMA, weekly data March 27, 2020
Note: Jardiance is part of the Boehringer Ingelheim and Lilly Diabetes Alliance
Q1 2020 CYRAMZA SALES INCREASED 21%

U.S. sales increased 19%
International sales increased 22%

Quarterly Sales by Major Geography

Note: Numbers may not add due to rounding.
Q1 2020 VERZENIO SALES INCREASED 72%

U.S. sales increased 38%
International sales were $59 million

Note: Numbers may not add due to rounding.

Source: IQVIA NPA NBRx 3MMA, weekly data March 27, 2020

Verzenio
Ibrance®
Kisqali®
Q1 2020 OLUMIANT SALES INCREASED 70%

U.S. sales increased 77%
International sales increased 70%

• Launched in the U.S. in July 2018
• Q1 sales driven by Germany and Japan
• Contributed 120bps to Q1 WW volume growth

Note: Numbers may not add due to rounding.
Q1 2020 EMGALITY SALES WERE $74 MILLION

U.S. sales were $67 million
International sales were $7 million

U.S. NBRx Share of Market

Source: IQMA NPA NBRx 3MMA, weekly data March 27, 2020

Note: Numbers may not add due to rounding.
Q1 2020 TYVYTY SALES WERE $57 MILLION

International sales were $57 million

- Launched in China in Q1 2019
- Part of Lilly collaboration with Innovent
- Contributed 210bps to Q1 WW volume growth

Note: Numbers may not add due to rounding.
Q1 2020 BAQSIMI SALES WERE $18 MILLION

U.S. sales were $16 million
International sales were $2 million

Note: Numbers may not add due to rounding.

Source: IQVIA NPA TRx weekly data March 27, 2020
Q1 2020 HUMALOG SALES DECREASED 5%

Millions

U.S. sales decreased 11%
International sales increased 5%

<table>
<thead>
<tr>
<th></th>
<th>Q1 2019</th>
<th>Q2 2019</th>
<th>Q3 2019</th>
<th>Q4 2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>U.S. sales</td>
<td>$731</td>
<td>$678</td>
<td>$649</td>
<td>$763</td>
</tr>
</tbody>
</table>

Note: Numbers may not add due to rounding.

Source: IQVIA NPA TRx 3MMA, weekly data March 27, 2020
## SELECT TRIALS - JARDIANCE

| Study     | Indication*                  | Title                                                                 | Phase | Patients | Primary Outcome**                                                                 | Primary Completion | Completion                  |
|-----------|------------------------------|                                                                      |       |          |                                                                                     |                   |                            |
| NCT03594110^  | Chronic Kidney Disease       | EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin) | 3     | 6000     | Composite primary outcome: Time to first occurrence of (i) kidney disease progression (defined as ESKD, a sustained decline in eGFR to <10 mL/min/1.73m², renal death, or a sustained decline of ≥40% in eGFR from randomization) or (ii) Cardiovascular death | J un 2022         | J un 2022                   |
| NCT03332212  | Heart Failure                | A Study That Looks at the Function of the Heart in Patients With Heart Failure Who Take Empagliflozin | 3     | 72       | Change from baseline to week 12 in PCr/ATP ratio in the resting state measured by 31P MRS. | May 2020          | May 2020                    |
| NCT03057977  | Heart Failure                | EMPagliflozin outcome Trial in Patients With Chronic Heart Failure With Reduced Ejection Fraction (EMPEROR-Reduced) | 3     | 3730     | Composite primary endpoint - Time to first event of adjudicated CV (Cardiovascular) death or adjudicated HHF (Hospitalisation for Heart Failure) in patients with Heart Failure with reduced Ejection Fraction (HFrEF) | J un 2020         | J ul 2020                   |
| NCT03057951  | Heart Failure                | EMPagliflozin outcome Trial in Patients With Chronic Heart Failure With Preserved Ejection Fraction (EMPEROR-Preserved) | 3     | 5982     | Composite primary endpoint - Time to first event of adjudicated CV (Cardiovascular) death or adjudicated HHF (Hospitalisation for Heart Failure) in patients with Heart Failure with preserved Ejection Fraction (HFpEF) | Oct 2020          | Nov 2020                    |
| NCT04157751  | Heart Failure                | A Study to Test the Effect of Empagliflozin in Patients Who Are in Hospital for Acute Heart Failure | 3     | 500      | The net clinical benefit, hierarchical composite endpoint composed of time to death, number of heart failure events (HFEs), time to first HFE, change in KCCQ-CSS from baseline after 90 days of treatment | Apr 2021          | J ul 2021                   |

In collaboration with Boehringer Ingelheim

^also lists Medical Research Council Population Health Research Unit, CTSU, University of Oxford (academic lead)

*Molecule may have multiple indications

**Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, April 15, 2020
## SELECT TRIALS – LEBRIKIZUMAB

<table>
<thead>
<tr>
<th>Study</th>
<th>Indication*</th>
<th>Title</th>
<th>Phase</th>
<th>Patients</th>
<th>Primary Outcome**</th>
<th>Primary Completion</th>
<th>Completion</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT04250337</td>
<td>Atopic Dermatitis</td>
<td>Safety and Efficacy of Lebrikizumab in Combination With Topical Corticosteroid in Moderate to Severe Atopic Dermatitis.</td>
<td>3</td>
<td>200</td>
<td>The primary efficacy endpoint is the percentage of patients with an IGA score of 0 or 1 and a reduction ≥2-points from Baseline to Week 16.</td>
<td>Feb 2021</td>
<td>May 2021</td>
</tr>
<tr>
<td>NCT04178967</td>
<td>Atopic Dermatitis</td>
<td>Evaluation of the Efficacy and Safety of Lebrikizumab in Moderate to Severe Atopic Dermatitis.</td>
<td>3</td>
<td>400</td>
<td>The primary efficacy endpoint is the percentage of patients with an IGA score of 0 or 1 and a reduction ≥2-points from Baseline to Week 16.</td>
<td>Jun 2021</td>
<td>Dec 2021</td>
</tr>
<tr>
<td>NCT04146363</td>
<td>Atopic Dermatitis</td>
<td>Evaluation of the Efficacy and Safety of Lebrikizumab in Moderate to Severe Atopic Dermatitis.</td>
<td>3</td>
<td>400</td>
<td>The primary efficacy endpoint is the percentage of patients with an IGA score of 0 or 1 and a reduction ≥2-points from Baseline to Week 16.</td>
<td>Jun 2021</td>
<td>Dec 2021</td>
</tr>
<tr>
<td>NCT04250350</td>
<td>Atopic Dermatitis</td>
<td>Study to Assess the Safety and Efficacy of Lebrikizumab in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis.</td>
<td>3</td>
<td>200</td>
<td>Number of adverse events from Baseline to Week 52.</td>
<td>Nov 2021</td>
<td>Jan 2022</td>
</tr>
</tbody>
</table>

*Molecule may have multiple indications

**Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, 11 a.m., April 22, 2020
### SELECT TRIALS – LYUMJ EV (URLi)

<table>
<thead>
<tr>
<th>Study</th>
<th>Indication*</th>
<th>Title</th>
<th>Phase</th>
<th>Patients</th>
<th>Primary Outcome**</th>
<th>Primary Completion</th>
<th>Completion</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT03740919</td>
<td>Type 1</td>
<td>A Study Comparing LY900014 to Insulin Lispro (Humalog) in Children and Adolescents With Type 1 Diabetes</td>
<td>3</td>
<td>945</td>
<td>Change from Baseline in Hemoglobin A1c (HbA1c) (Prandial Dosing)</td>
<td>Jul 2021</td>
<td>Jul 2021</td>
</tr>
<tr>
<td>NCT03952130</td>
<td>Type 1</td>
<td>A Study of LY900014 Compared to Insulin Lispro (Humalog) in Adults With Type 1 Diabetes</td>
<td>3</td>
<td>350</td>
<td>Change from Baseline in Hemoglobin A1c (HbA1c)</td>
<td>May 2022</td>
<td>May 2022</td>
</tr>
<tr>
<td>NCT03952143</td>
<td>Type 2</td>
<td>A Study of LY900014 Compared to Insulin Lispro (Humalog) in Adults With Type 2 Diabetes</td>
<td>3</td>
<td>564</td>
<td>Change from Baseline in Hemoglobin A1c (HbA1c)</td>
<td>Feb 2021</td>
<td>Feb 2021</td>
</tr>
</tbody>
</table>

*Molecule may have multiple indications

**Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, 11 a.m., April 22, 2020
## SELECT TRIALS – MIRIKIZUMAB

<table>
<thead>
<tr>
<th>Study</th>
<th>Indication*</th>
<th>Title</th>
<th>Phase</th>
<th>Patients</th>
<th>Primary Outcome**</th>
<th>Primary Completion</th>
<th>Completion</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT03535194</td>
<td>Psoriasis</td>
<td>A Study to Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2)</td>
<td>3</td>
<td>1443</td>
<td>Percentage of Participants with a Static Physician's Global Assessment (sPGA) of (0,1) with at Least a 2-point Improvement from Baseline</td>
<td>Mar 2020</td>
<td>Dec 2020</td>
</tr>
<tr>
<td>NCT03556202</td>
<td>Psoriasis</td>
<td>A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3)</td>
<td>3</td>
<td>1816</td>
<td>Percentage of Participants with a Static Physician's Global Assessment Among Those who Entered the Study with a sPGA of 0,1(sPGA) of (0,1)</td>
<td>May 2024</td>
<td>May 2024</td>
</tr>
<tr>
<td>NCT03926130</td>
<td>Crohn's Disease</td>
<td>A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease</td>
<td>3</td>
<td>1100</td>
<td>Percentage of Participants Achieving Endoscopic Response</td>
<td>Feb 2022</td>
<td>Jul 2023</td>
</tr>
<tr>
<td>NCT04232553</td>
<td>Crohn's Disease</td>
<td>A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease</td>
<td>3</td>
<td>778</td>
<td>Percentage of Participants Achieving Endoscopic Response</td>
<td>Nov 2023</td>
<td>Nov 2023</td>
</tr>
<tr>
<td>NCT03518086</td>
<td>Ulcerative Colitis</td>
<td>An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)</td>
<td>3</td>
<td>1160</td>
<td>Percentage of Participants in Clinical Remission</td>
<td>Sep 2020</td>
<td>Dec 2021</td>
</tr>
<tr>
<td>NCT03524092</td>
<td>Ulcerative Colitis</td>
<td>A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis</td>
<td>3</td>
<td>1044</td>
<td>Percentage of Participants in Clinical Remission</td>
<td>Jun 2021</td>
<td>Jun 2023</td>
</tr>
<tr>
<td>NCT03519945</td>
<td>Ulcerative Colitis</td>
<td>A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)</td>
<td>3</td>
<td>840</td>
<td>Percentage of Participants in Clinical Remission</td>
<td>Aug 2023</td>
<td>Aug 2023</td>
</tr>
</tbody>
</table>

*Source: clinicaltrials.gov, 11 a.m., April 22, 2020

*Molecule may have multiple indications

**Trial may have additional primary and other secondary outcomes
<table>
<thead>
<tr>
<th>Study</th>
<th>Indication*</th>
<th>Title</th>
<th>Phase</th>
<th>Patients</th>
<th>Primary Outcome**</th>
<th>Primary Completion</th>
<th>Completion</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT03899259</td>
<td>Alopecia Areata</td>
<td>A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata</td>
<td>3</td>
<td>476</td>
<td>Percentage of Participants Achieving Alopecia Areata Investigator Global Assessment (AA-IGA™) 0 or 1 with a ≥2 Point Improvement</td>
<td>Dec 2020</td>
<td>Mar 2022</td>
</tr>
<tr>
<td>NCT03570749</td>
<td>Alopecia Areata</td>
<td>A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata</td>
<td>2/3</td>
<td>725</td>
<td>Percentage of Participants Achieving Alopecia Areata Investigator Global Assessment (AA-IGA™) 0 or 1 with a ≥2 Point Improvement</td>
<td>Dec 2020</td>
<td>Mar 2022</td>
</tr>
<tr>
<td>NCT04280705</td>
<td>Corona Virus Infection</td>
<td>Adaptive COVID-19 Treatment Trial (ACTT)</td>
<td>3</td>
<td>572</td>
<td>Time to recovery</td>
<td>Apr 2023</td>
<td>Apr 2023</td>
</tr>
<tr>
<td>NCT03616964</td>
<td>Systemic Lupus Erythematosus</td>
<td>A Study of Baricitinib in Participants With Systemic Lupus Erythematosus</td>
<td>3</td>
<td>750</td>
<td>Percentage of Participants Achieving a Systemic Lupus Erythematosus Responder Index 4 (SRI-4) Response (High Dose)</td>
<td>May 2021</td>
<td>Jun 2021</td>
</tr>
<tr>
<td>NCT03616912</td>
<td>Systemic Lupus Erythematosus</td>
<td>A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus</td>
<td>3</td>
<td>750</td>
<td>Percentage of Participants Achieving a Systemic Lupus Erythematosus Responder Index 4 (SRI-4) Response (High Dose)</td>
<td>May 2021</td>
<td>Jun 2021</td>
</tr>
</tbody>
</table>

In collaboration with Incyte
^sponsored by National Institute of Allergy and Infectious Diseases (NIAID); baricitinib arm not yet reflected in clinicaltrials.gov

*Molecule may have multiple indications
**Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, 11 a.m., April 22, 2020
<table>
<thead>
<tr>
<th>Study</th>
<th>Indication*</th>
<th>Title</th>
<th>Phase</th>
<th>Patients</th>
<th>Primary Outcome**</th>
<th>Primary Completion</th>
<th>Completion</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT03899792</td>
<td>Medullary Thyroid Cancer</td>
<td>A Study of Oral LOXO-292 in Pediatric Patients With Advanced Solid or Primary Central Nervous System Tumors</td>
<td>1/2</td>
<td>100</td>
<td>To determine the safety of oral LOXO-292 in pediatric patients with advanced solid tumors: Dose limiting toxicities (DLTs)</td>
<td>Nov 2021</td>
<td>Oct 2022</td>
</tr>
<tr>
<td>NCT04211337</td>
<td>Medullary Thyroid Cancer</td>
<td>A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer</td>
<td>3</td>
<td>400</td>
<td>Treatment Failure-Free Survival (TFFS) by Blinded Independent Committee Review (BICR)</td>
<td>Feb 2023</td>
<td>Dec 2024</td>
</tr>
<tr>
<td>NCT03157128</td>
<td>Non-Small Cell Lung Cancer</td>
<td>Phase 1/2 Study of LOXO-292 in Patients With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer</td>
<td>1/2</td>
<td>970</td>
<td>Phase 1: Maximum tolerated dose (MTD)</td>
<td>Mar 2022</td>
<td>May 2022</td>
</tr>
<tr>
<td>NCT04194944</td>
<td>Non-Small Cell Lung Cancer</td>
<td>A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer</td>
<td>3</td>
<td>400</td>
<td>Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) (with or without Pembrolizumab)</td>
<td>Dec 2023</td>
<td>Apr 2026</td>
</tr>
<tr>
<td>NCT04280081</td>
<td>Solid Tumor</td>
<td>A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation</td>
<td>2</td>
<td>75</td>
<td>Overall Response Rate (ORR): Percentage of Participants with Complete Response (CR) or Partial Response (PR) by Independent Review Committee</td>
<td>May 2021</td>
<td>Apr 2023</td>
</tr>
</tbody>
</table>

*Molecule may have multiple indications

**Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, 11 a.m., April 22, 2020
## SELECT TRIALS – SOLANEZUMAB

<table>
<thead>
<tr>
<th>Study</th>
<th>Indication*</th>
<th>Title</th>
<th>Phase</th>
<th>Patients</th>
<th>Primary Outcome**</th>
<th>Primary Completion</th>
<th>Completion</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT02008357^</td>
<td>Cognition Disorders</td>
<td>Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss</td>
<td>3</td>
<td>1150</td>
<td>Change from Baseline of the Preclinical Alzheimer Cognitive Composite (PACC)</td>
<td>Jul 2022</td>
<td>Jul 2022</td>
</tr>
</tbody>
</table>

^also lists Alzheimer’s Therapeutic Research Institute

*Molecule may have multiple indications

**Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, January 18, 2020
## SELECT TRIALS – TANEZUMAB

<table>
<thead>
<tr>
<th>Study</th>
<th>Indication*</th>
<th>Title</th>
<th>Phase</th>
<th>Patients</th>
<th>Primary Outcome**</th>
<th>Primary Completion</th>
<th>Completion</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT02609828</td>
<td>Neoplasm Metastasis</td>
<td>Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid Therapy.</td>
<td>3</td>
<td>155</td>
<td>Change from baseline in daily average pain intensity in index bone metastasis cancer pain site</td>
<td>Aug 2020</td>
<td>May 2021</td>
</tr>
</tbody>
</table>

In collaboration with Pfizer

*Molecule may have multiple indications; Indication is for pain associated with the condition listed

**Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, March 23, 2020
## SELECT TRIALS – TIRZEPATIDE

<table>
<thead>
<tr>
<th>Study</th>
<th>Indication*</th>
<th>Title</th>
<th>Phase</th>
<th>Patients</th>
<th>Primary Outcome**</th>
<th>Primary Completion</th>
<th>Completion</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT04166773</td>
<td>Non-alcoholic Steato-hepatitis</td>
<td>A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH)</td>
<td>2</td>
<td>196</td>
<td>Percentage of Participants with Absence of NASH with no Worsening of Fibrosis on Liver Histology</td>
<td>Mar 2022</td>
<td>Mar 2022</td>
</tr>
<tr>
<td>NCT04184622</td>
<td>Overweight</td>
<td>A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight</td>
<td>3</td>
<td>2400</td>
<td>Percent Change from Baseline in Body Weight</td>
<td>Feb 2022</td>
<td>Apr 2024</td>
</tr>
<tr>
<td>NCT03954834</td>
<td>Type 2 Diabetes Mellitus</td>
<td>A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone</td>
<td>3</td>
<td>472</td>
<td>Change from Baseline in Hemoglobin A1c (HbA1c)</td>
<td>Oct 2020</td>
<td>Nov 2020</td>
</tr>
<tr>
<td>NCT03882970</td>
<td>Type 2 Diabetes Mellitus</td>
<td>A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes</td>
<td>3</td>
<td>1420</td>
<td>Change from Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg)</td>
<td>Dec 2020</td>
<td>Jan 2021</td>
</tr>
<tr>
<td>NCT04039503</td>
<td>Type 2 Diabetes</td>
<td>A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin</td>
<td>3</td>
<td>472</td>
<td>Change from Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg)</td>
<td>Jan 2021</td>
<td>Jan 2021</td>
</tr>
<tr>
<td>NCT03861039</td>
<td>Type 2 Diabetes Mellitus</td>
<td>A Long-term Safety Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes</td>
<td>3</td>
<td>441</td>
<td>Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration</td>
<td>Feb 2021</td>
<td>Mar 2021</td>
</tr>
<tr>
<td>NCT03987919</td>
<td>Type 2 Diabetes</td>
<td>A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes</td>
<td>3</td>
<td>1872</td>
<td>Change from Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg)</td>
<td>Feb 2021</td>
<td>Mar 2021</td>
</tr>
</tbody>
</table>

*Molecule may have multiple indications
**Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, 11 a.m., April 22, 2020

Not for promotional use

2020 Q1 EARNINGS
<table>
<thead>
<tr>
<th>Study</th>
<th>Indication*</th>
<th>Title</th>
<th>Phase</th>
<th>Patients</th>
<th>Primary Outcome**</th>
<th>Primary Completion</th>
<th>Completion</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT03861052</td>
<td>Type 2 Diabetes</td>
<td>A Study of Tirzepatide (LY3298176) Compared to Dulaglutide in Participants With Type 2 Diabetes</td>
<td>3</td>
<td>636</td>
<td>Change from Baseline in Hemoglobin A1c (HbA1c)</td>
<td>Mar 2021</td>
<td>Apr 2021</td>
</tr>
<tr>
<td>NCT03703062</td>
<td>Type 2 Diabetes Mellitus</td>
<td>A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk</td>
<td>3</td>
<td>1878</td>
<td>Change from Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg)</td>
<td>May 2021</td>
<td>Jun 2021</td>
</tr>
<tr>
<td>NCT04093752</td>
<td>Type 2 Diabetes</td>
<td>A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes on Metformin With or Without Sulfonylurea (SURPASS-AP-Combo)</td>
<td>3</td>
<td>956</td>
<td>Mean Change from Baseline in Hemoglobin A1c (HbA1c) (10 mg and 15 mg)</td>
<td>Feb 2022</td>
<td>Mar 2022</td>
</tr>
<tr>
<td>NCT04255433</td>
<td>Type 2 Diabetes Mellitus</td>
<td>A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes</td>
<td>3</td>
<td>12500</td>
<td>Time to First Occurrence of Death from Cardiovascular (CV) Causes, Myocardial Infarction (MI), or Stroke (MACE-3)</td>
<td>Oct 2024</td>
<td>Oct 2024</td>
</tr>
</tbody>
</table>

*Molecule may have multiple indications  
**Trial may have additional primary and other secondary outcomes  
Source: clinicaltrials.gov, 11 a.m., April 22, 2020
# SELECT TRIALS – VERZENIO

<table>
<thead>
<tr>
<th>Study</th>
<th>Indication*</th>
<th>Title</th>
<th>Phase</th>
<th>Patients</th>
<th>Primary Outcome**</th>
<th>Primary Completion</th>
<th>Completion</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT04031885</td>
<td>Metastatic Breast Cancer</td>
<td>A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer</td>
<td>4</td>
<td>300</td>
<td>Objective Response Rate (ORR): Percentage of Participants Who Achieve Complete Response (CR) or Partial Response (PR)</td>
<td>Apr 2021</td>
<td>Dec 2022</td>
</tr>
<tr>
<td>NCT03155997^</td>
<td>Breast Cancer</td>
<td>Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer</td>
<td>3</td>
<td>4580</td>
<td>Invasive Disease Free Survival (IDFS)</td>
<td>Apr 2021</td>
<td>Jun 2027</td>
</tr>
</tbody>
</table>

^also lists NSABP Foundation Inc

*Molecule may have multiple indications

**Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, 11 a.m., April 22, 2020
# SELECT TRIALS – EARLY PHASE COVID-19

<table>
<thead>
<tr>
<th>Molecule</th>
<th>Study</th>
<th>Indication*</th>
<th>Title</th>
<th>Phase</th>
<th>Patients</th>
<th>Primary Outcome**</th>
<th>Primary Completion</th>
<th>Completion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Angiopoietin 2 Mab</td>
<td>NCT04342897</td>
<td>COMD-19</td>
<td>A Study of LY3127804 in Participants With COMD-19</td>
<td>2</td>
<td>200</td>
<td>Number of Ventilator Free Days</td>
<td>Jul 2020</td>
<td>Jul 2020</td>
</tr>
</tbody>
</table>

*Molecule may have multiple indications

**Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, 11 a.m., April 22, 2020
# SELECT TRIALS – EARLY PHASE DIABETES

- **Molecule** may have multiple indications
- **Trial** may have additional primary and other secondary outcomes

<table>
<thead>
<tr>
<th>Molecule</th>
<th>Study</th>
<th>Indication*</th>
<th>Title</th>
<th>Phase</th>
<th>Patients</th>
<th>Primary Outcome**</th>
<th>Primary Completion</th>
<th>Completion</th>
</tr>
</thead>
<tbody>
<tr>
<td>GIP/GLP Coagonist Peptide</td>
<td>NCT04178733</td>
<td>Healthy</td>
<td>A Safety Study of LY3493269 Given as a Single Injection in Healthy Participants</td>
<td>1</td>
<td>54</td>
<td>Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration</td>
<td>Aug 2020</td>
<td>Aug 2020</td>
</tr>
<tr>
<td>GLP-1R NPA</td>
<td>NCT03929744</td>
<td>Healthy</td>
<td>A Study of LY3502970 in Healthy Participants</td>
<td>1</td>
<td>160</td>
<td>Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug</td>
<td>Oct 2020</td>
<td>Oct 2020</td>
</tr>
<tr>
<td>ANGPTL3/8 MAB</td>
<td>NCT04052594</td>
<td>Dyslipidemias</td>
<td>A Study of LY3475766 in Healthy Participants</td>
<td>1</td>
<td>55</td>
<td>Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug</td>
<td>Nov 2020</td>
<td>Nov 2020</td>
</tr>
<tr>
<td>Oxyntomodulin</td>
<td>NCT03928379</td>
<td>Diabetes Mellitus, Type 2</td>
<td>A Study of LY3305677 in Participants With Type 2 Diabetes</td>
<td>1</td>
<td>48</td>
<td>Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug</td>
<td>Nov 2020</td>
<td>Nov 2020</td>
</tr>
<tr>
<td>Basal Insulin - FC</td>
<td>NCT04276428</td>
<td>Diabetes Mellitus, Type 2</td>
<td>A Study of LY3209590 in Japanese Participants With Type 2 Diabetes Mellitus</td>
<td>1</td>
<td>27</td>
<td>Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug</td>
<td>Nov 2020</td>
<td>Nov 2020</td>
</tr>
<tr>
<td>GGG Tri-Agonist</td>
<td>NCT04143802</td>
<td>Diabetes Mellitus, Type 2</td>
<td>A Study of LY3437943 in Participants With Type 2 Diabetes Mellitus (T2DM)</td>
<td>1</td>
<td>75</td>
<td>Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug</td>
<td>Dec 2020</td>
<td>Dec 2020</td>
</tr>
<tr>
<td>GDF15 Agonist</td>
<td>NCT03764774</td>
<td>Healthy</td>
<td>A Study of LY3463251 in Healthy Participants</td>
<td>1</td>
<td>143</td>
<td>Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug</td>
<td>Dec 2020</td>
<td>Dec 2020</td>
</tr>
</tbody>
</table>

Source: clinicaltrials.gov, 11 a.m., April 22, 2020
## SELECT TRIALS – EARLY PHASE IMMUNOLOGY

<table>
<thead>
<tr>
<th>Molecule</th>
<th>Study</th>
<th>Indication*</th>
<th>Title</th>
<th>Phase</th>
<th>Patients</th>
<th>Primary Outcome**</th>
<th>Primary Completion</th>
<th>Completion</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD200R MAB Agonist</td>
<td>NCT04159701</td>
<td>Chronic Spontaneous Urticaria</td>
<td>A Study of LY3454738 in Adults With Chronic Spontaneous Urticaria</td>
<td>2</td>
<td>60</td>
<td>Mean Change from Baseline in Urticaria Activity Score Over 7 Days (UAS7)</td>
<td>Mar 2021</td>
<td>Aug 2021</td>
</tr>
<tr>
<td>CD200R MAB Agonist</td>
<td>NCT03750643</td>
<td>Dermatitis, Atopic</td>
<td>A Study of LY3454738 in Healthy Participants and Participants With Atopic Dermatitis</td>
<td>1</td>
<td>128</td>
<td>Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration</td>
<td>Jan 2022</td>
<td>Jan 2022</td>
</tr>
<tr>
<td>BTLA MAB Agonist</td>
<td>NCT03933943</td>
<td>Lupus Erythematosus, Systemic</td>
<td>A Study of LY3361237 in Participants With Systemic Lupus Erythematosus</td>
<td>1</td>
<td>24</td>
<td>Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug</td>
<td>J an 2021</td>
<td>J an 2021</td>
</tr>
<tr>
<td>IL-2 CONJ UGATE</td>
<td>NCT04119557</td>
<td>Psoriasis</td>
<td>A Study of LY3471851 in Participants With Psoriasis</td>
<td>1</td>
<td>40</td>
<td>Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug</td>
<td>Apr 2021</td>
<td>Apr 2021</td>
</tr>
<tr>
<td>IL-2 CONJ UGATE</td>
<td>NCT04081350</td>
<td>Dermatitis, Atopic</td>
<td>A Study of LY3471851 in Participants With Eczema</td>
<td>1</td>
<td>40</td>
<td>Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug</td>
<td>Apr 2021</td>
<td>Apr 2021</td>
</tr>
<tr>
<td>PD-1 Mab Agonist</td>
<td>NCT04152382</td>
<td>Psoriasis</td>
<td>A Safety Study of LY3462817 in Participants With Psoriasis</td>
<td>1</td>
<td>64</td>
<td>Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug</td>
<td>Dec 2022</td>
<td>Dec 2022</td>
</tr>
</tbody>
</table>

*Molecule may have multiple indications

**Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, 11 a.m., April 22, 2020
<table>
<thead>
<tr>
<th>Molecule</th>
<th>Study</th>
<th>Indication*</th>
<th>Title</th>
<th>Phase</th>
<th>Patients</th>
<th>Primary Outcome**</th>
<th>Primary Completion</th>
<th>Completion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mevidalen (D1 PAM)</td>
<td>NCT03305809</td>
<td>Lewy Body Dementia</td>
<td>A Study of LY3154207 in Participants With Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson’s Disease (PD) or Dementia With Lewy Bodies (DLB)</td>
<td>2</td>
<td>340</td>
<td>Change from Baseline in the Continuity of Attention (CoA) Composite Score of the Cognitive Drug Research Computerized Cognition Battery (CDR-CCB)</td>
<td>Jul 2020</td>
<td>Jul 2020</td>
</tr>
<tr>
<td>Donanemab (N3PG Aβ MAB)</td>
<td>NCT03367403</td>
<td>Alzheimer Disease</td>
<td>A Study of LY3002813 in Participants With Early Symptomatic Alzheimer’s Disease (TRAILBLAZER-ALZ)</td>
<td>2</td>
<td>266</td>
<td>Change from Baseline in the Integrated Alzheimer’s Disease Rating Scale (iADRS) Score</td>
<td>Dec 2020</td>
<td>Nov 2021</td>
</tr>
<tr>
<td>Zagotenemab (Tau MAB)</td>
<td>NCT03518073</td>
<td>Alzheimer Disease (AD)</td>
<td>A Study of LY3303560 in Participants With Early Symptomatic Alzheimer’s Disease</td>
<td>2</td>
<td>285</td>
<td>Change from Baseline on the integrated Alzheimer’s Disease Rating Scale (iADRS)</td>
<td>Aug 2021</td>
<td>Oct 2021</td>
</tr>
<tr>
<td>O-GlcNAcase Inh.</td>
<td>NCT04106206</td>
<td>Healthy</td>
<td>A Safety Study of LY3372689 in Healthy Participants</td>
<td>1</td>
<td>54</td>
<td>Number of Participants with One or More Serious Adverse Event(s) (SAEs) Observed by the Investigator During Study Drug Administration</td>
<td>Jun 2020</td>
<td>Jun 2020</td>
</tr>
<tr>
<td>D1 PAM II</td>
<td>NCT04014361</td>
<td>Healthy</td>
<td>A Study of LY3154885 in Healthy Participants</td>
<td>1</td>
<td>102</td>
<td>Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration</td>
<td>Jan 2021</td>
<td>Jan 2021</td>
</tr>
<tr>
<td>Mevidalen (D1 PAM)</td>
<td>NCT04258826</td>
<td>Healthy</td>
<td>A Study to Evaluate LY3154207 on the Brain of Healthy Participants</td>
<td>1</td>
<td>34</td>
<td>Change from Baseline in Intrinsic Functional Connectivity Among Resting-State Networks of the Brain</td>
<td>Sep 2021</td>
<td>Sep 2021</td>
</tr>
</tbody>
</table>

*Molecule may have multiple indications

**Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, 11 a.m., April 22, 2020
<table>
<thead>
<tr>
<th>Molecule</th>
<th>Study</th>
<th>Indication*</th>
<th>Title</th>
<th>Phase</th>
<th>Patients</th>
<th>Primary Outcome**</th>
<th>Primary Completion</th>
<th>Completion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Olaratumab</td>
<td>NCT02659020</td>
<td>Soft Tissue Sarcoma</td>
<td>A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma</td>
<td>1/2</td>
<td>310</td>
<td>Phase 1b: Recommended Phase 2 Dose of Olaratumab: Number of Participants with Dose Limiting Toxicity (DLT)</td>
<td>Jul 2020</td>
<td>Jul 2021</td>
</tr>
<tr>
<td>BTK Inhibitor</td>
<td>NCT03740529</td>
<td>Chronic Lymphocytic Leukemia</td>
<td>A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL</td>
<td>1/2</td>
<td>403</td>
<td>Maximum Tolerated Dose (MTD)</td>
<td>Oct 2020</td>
<td>Apr 2021</td>
</tr>
<tr>
<td>Olaratumab</td>
<td>NCT03086369</td>
<td>Metastatic Pancreatic Cancer</td>
<td>A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer</td>
<td>1/2</td>
<td>186</td>
<td>Number of Participants with Dose Limiting Toxicities (DLTs) Phase 1b</td>
<td>Jan 2021</td>
<td>Aug 2022</td>
</tr>
<tr>
<td>Aur A Kinase Inhibitor</td>
<td>NCT03898791</td>
<td>Small Cell Lung Cancer</td>
<td>A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung Cancer</td>
<td>1/2</td>
<td>64</td>
<td>Number of Participants with Dose Reductions</td>
<td>Feb 2021</td>
<td>Feb 2021</td>
</tr>
<tr>
<td>KRAS G12C Inhibitor</td>
<td>NCT04165031</td>
<td>Advanced Solid Tumor</td>
<td>A Study of LY3499446 In Participants With Advanced Solid Tumors With KRAS G12C Mutation</td>
<td>1/2</td>
<td>230</td>
<td>Phase 1: Number or Participants with Dose Limiting Toxicities (DLTs)</td>
<td>Dec 2021</td>
<td>Dec 2021</td>
</tr>
</tbody>
</table>

*Molecule may have multiple indications

**Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, 11 a.m., April 22, 2020
### SELECT TRIALS – EARLY PHASE ONCOLOGY (CONTINUED)

<table>
<thead>
<tr>
<th>Molecule</th>
<th>Study</th>
<th>Indication*</th>
<th>Title</th>
<th>Phase</th>
<th>Patients</th>
<th>Primary Outcome**</th>
<th>Primary Completion</th>
<th>Completion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Olaratumab</td>
<td>NCT03126591</td>
<td>Soft Tissue Sarcoma</td>
<td>A Study of Olaratumab (LY3012207) Plus Pembrolizumab in Participants With Advanced or Metastatic Soft Tissue Sarcoma</td>
<td>1</td>
<td>41</td>
<td>Number of Participants with Olaratumab Dose Limiting Toxicities (DLTs)</td>
<td>Jul 2020</td>
<td>Oct 2020</td>
</tr>
<tr>
<td>Aur A Kinase Inhibitor</td>
<td>NCT03955939</td>
<td>Metastatic Breast Cancer</td>
<td>A Study of LY3295668 Erbumine in Participants With Breast Cancer That Has Spread to Other Parts of the Body</td>
<td>1</td>
<td>100</td>
<td>Number of Participants with Dose Reductions</td>
<td>Mar 2021</td>
<td>Mar 2021</td>
</tr>
<tr>
<td>CD73 Inhibitor</td>
<td>NCT04148937</td>
<td>Advanced Cancer</td>
<td>A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer</td>
<td>1</td>
<td>120</td>
<td>Number of Participants with Dose Limiting Toxicity (DLT)</td>
<td>Jun 2021</td>
<td>Dec 2022</td>
</tr>
<tr>
<td>ERK Inhibitor</td>
<td>NCT02857270</td>
<td>Advanced Cancer</td>
<td>A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer</td>
<td>1</td>
<td>272</td>
<td>Number of Participants with LY3214996 Dose Limiting Toxicities (DLTs)</td>
<td>Dec 2021</td>
<td>Dec 2021</td>
</tr>
<tr>
<td>SERD</td>
<td>NCT04188548</td>
<td>Breast Cancer</td>
<td>A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer</td>
<td>1</td>
<td>186</td>
<td>Number of Participants with Dose Limiting Toxicities (DLTs)</td>
<td>Oct 2022</td>
<td>Apr 2023</td>
</tr>
<tr>
<td>Aur A Kinase Inhibitor</td>
<td>NCT04106219</td>
<td>Neuroblastoma</td>
<td>A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma</td>
<td>1</td>
<td>71</td>
<td>Number of Participants with Dose Limiting Toxicities (DLTs)</td>
<td>Apr 2024</td>
<td>Apr 2025</td>
</tr>
</tbody>
</table>

* Molecule may have multiple indications
** Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, 11 a.m., April 22, 2020

Not for promotional use
## SELECT TRIALS – EARLY PHASE PAIN

<table>
<thead>
<tr>
<th>Molecule</th>
<th>Study</th>
<th>Indication*</th>
<th>Title</th>
<th>Phase</th>
<th>Patients</th>
<th>Primary Outcome**</th>
<th>Primary Completion</th>
<th>Completion</th>
</tr>
</thead>
<tbody>
<tr>
<td>TRPA1 Antagonist</td>
<td>NCT03977974</td>
<td>Healthy</td>
<td>A Study of LY3526318 in Healthy Participants</td>
<td>1</td>
<td>80</td>
<td>Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration</td>
<td>Apr 2020</td>
<td>Apr 2020</td>
</tr>
<tr>
<td>SSTR4 Agonist</td>
<td>NCT04156750</td>
<td>Healthy</td>
<td>A Study of LY3556050 in Healthy Participants</td>
<td>1</td>
<td>51</td>
<td>Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration</td>
<td>Jul 2020</td>
<td>Jul 2020</td>
</tr>
</tbody>
</table>

*Molecule may have multiple indications

**Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, 11 a.m., April 22, 2020
Lilly